Comment by s1artibartfast

Yeah, I think that's especially relevant here too and reinforces the phenomenon where US hcps will opt for the best independent of price, even if the marginal benefit is vanishingly small or hypothetical/not data driven.

Some providers did opt to self-compound avastin for off label use mostly in Europe but also in the US.

The idea that Pharma companies would pass on developing a product 1% better than keytruda, or that hcps would pass on buying is laughable